A senior executive at Vector Virology Center, the site where the EpiVacCorona vaccine is manufactured, was dismissed after a personal relationship with a subordinate came to light. The claim emerged from a Telegram channel known as Basis and has since circulated widely in media circles.
Reports from Basis indicate that the departure was tied to the nature of the relationship, noting that the subordinate held a significant role within the Vector center. The publication suggests that the term “work” may not fully describe the arrangement, asserting that the woman maintains an irregular schedule and is present at the facility only when she chooses to be.
There is also speculation that Vector staff reacted negatively to the situation and voiced concerns to the center’s leadership. The accounts describe a confrontation with the top director that allegedly did not resolve the tensions.
Earlier statements attributed to the authorities indicate that the executive, identified as Rinat Maksyutov, was removed on grounds of a conflict of interest and potential breaches of anti-corruption rules. Officials have claimed they implemented steps to address the situation and to review the facts that surfaced during the inquiry.
The broader context involves ongoing scrutiny of governance and ethics within research organizations and state-affiliated healthcare production sites. Observers note that such personnel changes can have ripple effects on public trust, funding, and the perceived integrity of vaccine programs. Analysts emphasize the importance of transparent processes when personnel actions touch on leadership in critical science facilities and public health initiatives. Attribution for the initial disclosures remains with Basis, a channel that has been cited by multiple outlets for sharing early information about internal personnel matters.
Industry observers stress that independent investigations and official confirmations are essential to separate speculation from fact. They recommend reviewing formal statements from Vector Virology Center and relevant regulatory bodies to understand the full scope of the case, including any disciplinary actions, policy reviews, or changes in governance that may follow. The situation highlights the need for clear internal controls and ethical guidelines in organizations responsible for vaccine development and production, especially in times of heightened public attention to immunization programs and scientific oversight. Basis’s reporting should be weighed alongside subsequent official updates as the story develops, with attention paid to timelines, documented evidence, and corroborating sources.